Prognostic factors in small cell lung cancer: A new prognostic index in Korean patients

Soojung Hong, ByoungChul Cho, Hye Jin Choi, Minkyu Jung, Soo Hyeon Lee, Kyung Soo Park, Se Kyu Kim, Joo Hang Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: The aims of this study were to identify prognostic factors for overall survival (OS) in patients with small cell lung cancer (SCLC) and to construct a prognostic index on the basis of their expected OS. Long-term survivors were also given special attention. Methods: We retrospectively analyzed 295 patients diagnosed with SCLC from January 2002 to September 2007 at the Severance Hospital, Seoul, Republic of Korea. Patient history was reviewed regarding both clinical and tumor-related markers, and treatment-related factors were also evaluated. Results: There were 131 (44.4%) patients with limited disease (LD) and 164 (55.6%) with extensive disease (ED). Median follow-up lasted 9.4 months. Objective response to chemotherapy was 66.8%. The median survival time (MST) was 11.2 months in all patients, 20.4 months in LD patients, and 7.7 months in ED patients. The median progression-free survival was 9.4 months. Independent prognostic factors for overall survival (OS) were extent of disease, performance status, and CYFRA 21-1 level. We classified all patients into four groups based on the results of multivariate analysis using classification and regression tree analysis. Median survival times were 22.7, 13.7, 8.5, and 3.2 months, respectively. A total of 51 (17.3%) patients from the entire study population were evaluated for long-term survival, which was defined as survival >2 years. Their MST was 43.1 months, and extent of disease, performance status, and CYFRA 21-1 were independent prognostic factors for long-term survival. Conclusions: We confirmed the well-known prognosticators, disease extent and performance status, in our patients, but further identified CYFRA 21-1 as independent prognostic factor. A prognostic index was constructed to create four classifications of SCLC considering these variables.

Original languageEnglish
Pages (from-to)293-300
Number of pages8
JournalOncology
Volume79
Issue number3-4
DOIs
Publication statusPublished - 2011 Mar 1

Fingerprint

Small Cell Lung Carcinoma
Survival
Republic of Korea
Tumor Biomarkers
Disease-Free Survival
Survivors
Multivariate Analysis
Regression Analysis
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hong, S., Cho, B., Choi, H. J., Jung, M., Lee, S. H., Park, K. S., ... Kim, J. H. (2011). Prognostic factors in small cell lung cancer: A new prognostic index in Korean patients. Oncology, 79(3-4), 293-300. https://doi.org/10.1159/000323333
Hong, Soojung ; Cho, ByoungChul ; Choi, Hye Jin ; Jung, Minkyu ; Lee, Soo Hyeon ; Park, Kyung Soo ; Kim, Se Kyu ; Kim, Joo Hang. / Prognostic factors in small cell lung cancer : A new prognostic index in Korean patients. In: Oncology. 2011 ; Vol. 79, No. 3-4. pp. 293-300.
@article{bbbf3a014eab4eb49ae4b3bc97859fd5,
title = "Prognostic factors in small cell lung cancer: A new prognostic index in Korean patients",
abstract = "Objective: The aims of this study were to identify prognostic factors for overall survival (OS) in patients with small cell lung cancer (SCLC) and to construct a prognostic index on the basis of their expected OS. Long-term survivors were also given special attention. Methods: We retrospectively analyzed 295 patients diagnosed with SCLC from January 2002 to September 2007 at the Severance Hospital, Seoul, Republic of Korea. Patient history was reviewed regarding both clinical and tumor-related markers, and treatment-related factors were also evaluated. Results: There were 131 (44.4{\%}) patients with limited disease (LD) and 164 (55.6{\%}) with extensive disease (ED). Median follow-up lasted 9.4 months. Objective response to chemotherapy was 66.8{\%}. The median survival time (MST) was 11.2 months in all patients, 20.4 months in LD patients, and 7.7 months in ED patients. The median progression-free survival was 9.4 months. Independent prognostic factors for overall survival (OS) were extent of disease, performance status, and CYFRA 21-1 level. We classified all patients into four groups based on the results of multivariate analysis using classification and regression tree analysis. Median survival times were 22.7, 13.7, 8.5, and 3.2 months, respectively. A total of 51 (17.3{\%}) patients from the entire study population were evaluated for long-term survival, which was defined as survival >2 years. Their MST was 43.1 months, and extent of disease, performance status, and CYFRA 21-1 were independent prognostic factors for long-term survival. Conclusions: We confirmed the well-known prognosticators, disease extent and performance status, in our patients, but further identified CYFRA 21-1 as independent prognostic factor. A prognostic index was constructed to create four classifications of SCLC considering these variables.",
author = "Soojung Hong and ByoungChul Cho and Choi, {Hye Jin} and Minkyu Jung and Lee, {Soo Hyeon} and Park, {Kyung Soo} and Kim, {Se Kyu} and Kim, {Joo Hang}",
year = "2011",
month = "3",
day = "1",
doi = "10.1159/000323333",
language = "English",
volume = "79",
pages = "293--300",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3-4",

}

Hong, S, Cho, B, Choi, HJ, Jung, M, Lee, SH, Park, KS, Kim, SK & Kim, JH 2011, 'Prognostic factors in small cell lung cancer: A new prognostic index in Korean patients', Oncology, vol. 79, no. 3-4, pp. 293-300. https://doi.org/10.1159/000323333

Prognostic factors in small cell lung cancer : A new prognostic index in Korean patients. / Hong, Soojung; Cho, ByoungChul; Choi, Hye Jin; Jung, Minkyu; Lee, Soo Hyeon; Park, Kyung Soo; Kim, Se Kyu; Kim, Joo Hang.

In: Oncology, Vol. 79, No. 3-4, 01.03.2011, p. 293-300.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic factors in small cell lung cancer

T2 - A new prognostic index in Korean patients

AU - Hong, Soojung

AU - Cho, ByoungChul

AU - Choi, Hye Jin

AU - Jung, Minkyu

AU - Lee, Soo Hyeon

AU - Park, Kyung Soo

AU - Kim, Se Kyu

AU - Kim, Joo Hang

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Objective: The aims of this study were to identify prognostic factors for overall survival (OS) in patients with small cell lung cancer (SCLC) and to construct a prognostic index on the basis of their expected OS. Long-term survivors were also given special attention. Methods: We retrospectively analyzed 295 patients diagnosed with SCLC from January 2002 to September 2007 at the Severance Hospital, Seoul, Republic of Korea. Patient history was reviewed regarding both clinical and tumor-related markers, and treatment-related factors were also evaluated. Results: There were 131 (44.4%) patients with limited disease (LD) and 164 (55.6%) with extensive disease (ED). Median follow-up lasted 9.4 months. Objective response to chemotherapy was 66.8%. The median survival time (MST) was 11.2 months in all patients, 20.4 months in LD patients, and 7.7 months in ED patients. The median progression-free survival was 9.4 months. Independent prognostic factors for overall survival (OS) were extent of disease, performance status, and CYFRA 21-1 level. We classified all patients into four groups based on the results of multivariate analysis using classification and regression tree analysis. Median survival times were 22.7, 13.7, 8.5, and 3.2 months, respectively. A total of 51 (17.3%) patients from the entire study population were evaluated for long-term survival, which was defined as survival >2 years. Their MST was 43.1 months, and extent of disease, performance status, and CYFRA 21-1 were independent prognostic factors for long-term survival. Conclusions: We confirmed the well-known prognosticators, disease extent and performance status, in our patients, but further identified CYFRA 21-1 as independent prognostic factor. A prognostic index was constructed to create four classifications of SCLC considering these variables.

AB - Objective: The aims of this study were to identify prognostic factors for overall survival (OS) in patients with small cell lung cancer (SCLC) and to construct a prognostic index on the basis of their expected OS. Long-term survivors were also given special attention. Methods: We retrospectively analyzed 295 patients diagnosed with SCLC from January 2002 to September 2007 at the Severance Hospital, Seoul, Republic of Korea. Patient history was reviewed regarding both clinical and tumor-related markers, and treatment-related factors were also evaluated. Results: There were 131 (44.4%) patients with limited disease (LD) and 164 (55.6%) with extensive disease (ED). Median follow-up lasted 9.4 months. Objective response to chemotherapy was 66.8%. The median survival time (MST) was 11.2 months in all patients, 20.4 months in LD patients, and 7.7 months in ED patients. The median progression-free survival was 9.4 months. Independent prognostic factors for overall survival (OS) were extent of disease, performance status, and CYFRA 21-1 level. We classified all patients into four groups based on the results of multivariate analysis using classification and regression tree analysis. Median survival times were 22.7, 13.7, 8.5, and 3.2 months, respectively. A total of 51 (17.3%) patients from the entire study population were evaluated for long-term survival, which was defined as survival >2 years. Their MST was 43.1 months, and extent of disease, performance status, and CYFRA 21-1 were independent prognostic factors for long-term survival. Conclusions: We confirmed the well-known prognosticators, disease extent and performance status, in our patients, but further identified CYFRA 21-1 as independent prognostic factor. A prognostic index was constructed to create four classifications of SCLC considering these variables.

UR - http://www.scopus.com/inward/record.url?scp=79952610948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952610948&partnerID=8YFLogxK

U2 - 10.1159/000323333

DO - 10.1159/000323333

M3 - Article

C2 - 21412014

AN - SCOPUS:79952610948

VL - 79

SP - 293

EP - 300

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -